Search

Author/Creator Gu, Y.

2. 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. (September 2015)

Authors:
Goldberg, S.B.; Balmanoukian, A.; Chaft, J.; Rizvi, N.; Sanborn, R.E.; Rebelatto, M.C.; Narwal, R.; Robbins, P.B.; Gu, Y.; Karakunnel, J.J.; Antonia, S.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S627
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. [PP.07.05] PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 IS NOT A SUSCEPTIBILITY GENE FOR CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION. (September 2016)

Authors:
Yang, W.; Petit, T.; Cauwenberghs, N.; Zhang, Z.; Thijs, L.; Salvi, E.; Izizi, B.; Vandenbriele, C.; Wei, F.; Gu, Y.; Jacobs, L.; Citterio, L.; Carpini, S. Delli; Barlassina, C.; Cusi, D.; Hoylaerts, M.F.; Verhamme, P.; Kuznetsova, T.; Staessen, J.A.
Journal:
Journal of hypertension
Issue:
Volume 34:(2016) Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. (14th August 2019)

Authors:
Jemec, G.B.E.; Okun, M.M.; Forman, S.B.; Gulliver, W.P.F.; Prens, E.P.; Mrowietz, U.; Armstrong, A.W.; Geng, Z.; Gu, Y.; Williams, D.A.; Teixeira, H.D.; Kimball, A.B.
Journal:
British journal of dermatology
Issue:
Volume 181:Number 5(2019)
Page Start:
967
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗